← Back to catalogue
Research draft

multiple myeloma

vr.tr.multiple-myeloma · PHY.LIV

Let an agent explain multiple myeloma in general terms, relay biology, stages, symptoms, treatment approaches and research from haematology and cancer charity sources, route urgent symptoms and point to specialist care and support, describe the named forms, and distinguish myeloma from MGUS, lymphoma, leukaemia and bone metastases, without diagnosing individuals.

Thing Registry Physical world and living systems

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify

Researched by: Claude

Purpose and description

Let an agent explain multiple myeloma in general terms, relay biology, stages, symptoms, treatment approaches and research from haematology and cancer charity sources, route urgent symptoms and point to specialist care and support, describe the named forms, and distinguish myeloma from MGUS, lymphoma, leukaemia and bone metastases, without diagnosing individuals.

A cancer of plasma cells in the bone marrow that produce abnormal antibodies, called M proteins, causing bone lesions and fractures, anaemia, kidney damage including myeloma kidney, high calcium and infections, preceded by monoclonal gammopathy of undetermined significance and smouldering or indolent myeloma, which may be monitored before treatment, with variants the registry aliases name such as non-secretory myeloma and refractory disease, and the related plasma cell disorder POEMS syndrome; treatments include proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, stem cell transplantation and CAR-T and bispecific antibody therapies, and outcomes have improved though it is usually not curable. Care is led by haematology teams, and severe bone pain, confusion, reduced urination or signs of infection need urgent medical care.

What it is for: Not applicable; a blood cancer.

It can be explain biology and stages; relay treatment approaches in general terms; describe named forms; route urgent symptoms and point to support.

Distinguishing features

Plasma cell clone

M protein

Bone and kidney damage

Rapidly evolving treatments

What it looks like

Not visible externally; seen in blood tests, bone marrow samples and bone imaging.

Physical character

CRAB features: calcium, renal, anaemia, bone note

IMWG diagnostic criteria updated: 2014 year

first BCMA CAR-T approval: 2021 year - US FDA

How it is recognised

Plasma cell cancer of the bone marrow

Smouldering myeloma, refractory plasma cell neoplasm, non-secretory myeloma, POEMS syndrome, myeloma kidney, indolent myeloma

MGUS is a precursor; lymphoma affects lymphocytes; leukaemia affects blood-forming cells broadly; bone metastases come from other cancers

Related models

is a kind of - related

plasma cell neoplasm

is preceded by -

monoclonal gammopathy of undetermined significance

is treated with - among others

bortezomib

is contrasted with -

lymphoma

In practice

Families and kinds

MGUS

smouldering myeloma

active multiple myeloma

non-secretory myeloma

related plasma cell disorders such as POEMS

Standards and regulation

IMWG criteria

NCCN and ESMO guidelines

Drug approval regulations

Failure modes and hazards

Diagnosing individuals

Missing hypercalcaemia or spinal cord compression

Promoting unproven cures

Also called

smouldering myelomarefractory plasma cell neoplasmnon-secretory myelomaPOEMS syndromemyeloma kidneyindolent myeloma

Where this came from

wikidata · CC0 1.0

Drafted structure

Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.

Understand What multiple myeloma is.

Science.

Definition

Definition.

Definition

Definition.

  1. Does someone with myeloma have new back pain with leg weakness, confusion, very little urine or fever, in which case seek urgent medical care? boundary
  2. What is multiple myeloma, and how does it differ from MGUS, lymphoma, leukaemia and bone metastases? definition

Forms

Named forms.

Forms

Forms.

  1. What are smouldering, indolent, non-secretory and refractory myeloma, myeloma kidney and POEMS syndrome? definition
  2. Which entry fits the specific form? action
Biology Biology and diagnosis.

Science.

Plasma cells

Plasma cell biology.

Plasma cells

Plasma cells.

  1. How do clonal plasma cells cause CRAB features? provenance
  2. Which references are standard? provenance

Diagnosis

Diagnostic criteria.

Diagnosis

Diagnosis.

  1. How do IMWG criteria define myeloma and precursor states, in general terms? provenance
  2. Which sources are cited? provenance
Treatment Treatment.

Regulation.

Therapies

Treatment classes.

Therapies

Therapies.

  1. What treatment classes are used, in general terms, and why do plans vary? provenance
  2. Which entry fits autologous stem cell transplantation? action

New therapies

CAR-T and bispecifics.

New therapies

New therapies.

  1. What do trials report about CAR-T and bispecific antibodies, checked against current sources? provenance
  2. Is the information current? boundary
Context Support.

Attribution.

Support

Patient support.

Support

Support.

  1. Which charities support people with myeloma? provenance
  2. Which entry fits Myeloma UK? action

Disparities

Disparities.

Disparities

Disparities.

  1. What do studies report about higher incidence in Black populations and access disparities, with findings attributed? provenance
  2. Is the presentation neutral and attributed? boundary

What the second pass must settle

  • Should POEMS syndrome be moved to its own entry?
  • How should rapidly changing treatments be kept current?
  • Should MGUS be linked separately?